A Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent Non-Hodgkin Lymphoma | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
A Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent Non-Hodgkin Lymphoma	B-cell neoplasm, Hemic and Lymphatic Diseases, Lymphoma, B-Cell, Marginal Zone, Neoplasms by Histologic Type, follicular lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, marginal zone lymphoma, neoplasm	Recruiting	Phase 1 / Phase 2	2026-01-30		NCT04669171

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Enterome	1

12 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
CHU d'Amiens-Picardie - Hopital SUD	Amiens	France	1
Clinica Universidad De Navarra	Pamplona	Spain	20
Clinica Universidad de Navarra	Madrid	Spain	6
Dana Farber Cancer Institute	Boston	United States	300
Hospital Clinico Universitario de Salamanca	Salamanca	Spain	7
IRCCS Policlinico San Matteo Foundation - University of Pavia	Pavia	Italy	1
IRCCS Policlinico San Matteo Foundation - University of Pavia	Naples	Italy	1
Mayo Clinic	Rochester	United States	664
University Hospital Vall d'Hebron, Institute of Oncology	Barcelona	Spain	1
University of Bologna	Bologna	Italy	6
University of Rochester Medical Center (URMC) - Wilmot Cancer Institute (WCI) (James P. Wilmot Cancer Center)	Rochester	United States	1
University of Washington-Seattle Cancer Care Alliance	Seattle	United States	2